Innovative Medicine

· New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain · Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more than twice as many patients on nipocalimab compared to placeboc · Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren’s disease including these measures critical to patients

· Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 · ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill

· Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 · First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need 2-3 · Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways – two key drivers of tumor progression in head and neck cancer 2

Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC

· New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery · Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone · Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026

· First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer · New first-line head and neck cancer data highlight the potential of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and its dual EGFR-MET approach, building on the established role of RYBREVANT®-based regimens in lung cancer · New ERLEADA® (apalutamide) substudy findings in prostate cancer build on the primary results presented at ASCO 2026

Patient data from the Phase 2 study of nipocalimab in Sjögren’s disease identify improvements in most core patient-relevant symptoms, with associated improvements in health-related quality of life Positive Phase 2 data support continued development of nipocalimab in systemic lupus erythematosus; Phase 3 study is recruiting

· TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group · These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn’s disease

· New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure · Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups · Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn’s disease with perianal fistula in more than 20 years